Table 2.
“Rescue” of TGF-β1-stimulated PAI-1 induction in EGFR−/− fibroblasts engineered to re-express EGFR1.
| Cell type/treatmenta,b | PAI-1 expression level |
|---|---|
| EGFR−/−/−TGF-β1 | 1 ± 0 |
| EGFR−/−/+TGF-β1 | 1.3 ± 0.4 |
| EGFR−/−→EGFR+/+/−TGF-β1 | 2.8 ± 0.4 |
| EGFR−/−→EGFR+/+/+TGF-β1 | 11.0 ± 2.8 |
a
EGFR−/− MEFs were infected (MOI =50–100) with adenoviruses bearing either control (GFP) or wild-type human EGFR expression constructs in low-serum-containing medium. Indicated cell types (EGFR-null MEFs or cells engineered to re-express a wild-type EGFR) were maintained in growth factor-free medium (−TGF-β1) or stimulated with TGF-β1 (+TGF-β1; 1 ng/ml) for 5 hours.
b
Western blots of PAI-1 levels in cellular extracts were quantified by densitometry; data is the mean ± standard deviation of triplicate independent experiments.